OPERA I/OPERA II results for ocrelizumab in RRMS

 

REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – The much-anticipated results of the OPERA I and II studies of ocrelizumab in relapsing MS were presented on Friday and indicate that the anti-CD20 monoclonal antibody is highly effective compared to interferon-beta-1a s.c. (Hauser et al. ECTRIMS 2015; abstract 190).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page